Mortality Advantage With Pimavanserin in Parkinson's Psychosis?

Use of pimavanserin was associated with 35% lower mortality for patients with Parkinson's disease–related psychosis compared with atypical antipsychotics, a large new real-world analysis shows.
Medscape Medical News

source https://www.medscape.com/viewarticle/977263?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost